NT 3 Growth Factor Receptor (TrkC Tyrosine Kinase or GP145 TrkC or Neurotrophic Tyrosine Kinase Receptor Type 3 or NTRK3 or EC 2.7.10.1) - Pipeline Review, H1 2018

  • ID: 4461746
  • Drug Pipelines
  • 62 pages
  • Global Markets Direct
1 of 5

FEATURED COMPANIES

  • AstraZeneca Plc
  • Daiichi Sankyo Co Ltd
  • Handok Inc
  • Ignyta Inc
  • Loxo Oncology Inc
  • Plexxikon Inc
  • MORE
NT 3 Growth Factor Receptor (TrkC Tyrosine Kinase or GP145 TrkC or Neurotrophic Tyrosine Kinase Receptor Type 3 or NTRK3 or EC 2.7.10.1) - Pipeline Review, H1 2018

Summary:

According to the recently published report 'NT 3 Growth Factor Receptor - Pipeline Review, H1 2018'; NT 3 Growth Factor Receptor (TrkC Tyrosine Kinase or GP145 TrkC or Neurotrophic Tyrosine Kinase Receptor Type 3 or NTRK3 or EC 2.7.10.1) pipeline Target constitutes close to 8 molecules. Out of which approximately 8 molecules are developed by Companies.

NT 3 Growth Factor Receptor (TrkC Tyrosine Kinase or GP145 TrkC or Neurotrophic Tyrosine Kinase Receptor Type 3 or NTRK3 or EC 2.7.10.1) - Tropomyosin receptor kinase C (TrkC) or NT-3 growth factor receptor is a protein encoded by the NTRK3 gene. It is involved in nervous system and probably heart development. Upon binding of its ligand neurotrophin-3, NTRK3 autophosphorylates and activates different signaling pathways, including the AKT and the MAPK pathways that control cell survival and differentiation.

The report 'NT 3 Growth Factor Receptor - Pipeline Review, H1 2018' outlays comprehensive information on the NT 3 Growth Factor Receptor (TrkC Tyrosine Kinase or GP145 TrkC or Neurotrophic Tyrosine Kinase Receptor Type 3 or NTRK3 or EC 2.7.10.1) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type; that are being developed by Companies / Universities.

It also reviews key players involved in NT 3 Growth Factor Receptor (TrkC Tyrosine Kinase or GP145 TrkC or Neurotrophic Tyrosine Kinase Receptor Type 3 or NTRK3 or EC 2.7.10.1) targeted therapeutics development with respective active and dormant or discontinued projects. Currently, The molecules developed by companies in Pre-Registration, Phase III, Phase I, Preclinical and Discovery stages are 1, 1, 2, 2 and 2 respectively. Report covers products from therapy areas Oncology, Central Nervous System and Genetic Disorders which include indications Solid Tumor, Non-Small Cell Lung Cancer, Bile Duct Cancer (Cholangiocarcinoma), Brain Cancer, Breast Cancer, Central Nervous System (CNS) Tumor, Colorectal Cancer, Fibrosarcoma, Neuroblastoma, Neuroendocrine Tumors, Ovarian Cancer, Pancreatic Cancer, Salivary Gland Cancer, Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia), Alzheimer's Disease, Anaplastic Large Cell Lymphoma (ALCL), Astrocytoma, Biliary Tumor, Charcot-Marie-Tooth Disease, Gastrointestinal Stromal Tumor (GIST), Glioblastoma Multiforme (GBM), Head And Neck Cancer, Head And Neck Cancer Squamous Cell Carcinoma, Melanoma, Metastatic Colorectal Cancer, Metastatic Melanoma, Non-Small Cell Lung Carcinoma, Papillary Thyroid Cancer, Parkinson's Disease, Pontine Glioma, Prostate Cancer, Renal Cell Carcinoma, Soft Tissue Sarcoma and Thyroid Cancer.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope:
  • The report provides a snapshot of the global therapeutic landscape for NT 3 Growth Factor Receptor (TrkC Tyrosine Kinase or GP145 TrkC or Neurotrophic Tyrosine Kinase Receptor Type 3 or NTRK3 or EC 2.7.10.1)
  • The report reviews NT 3 Growth Factor Receptor (TrkC Tyrosine Kinase or GP145 TrkC or Neurotrophic Tyrosine Kinase Receptor Type 3 or NTRK3 or EC 2.7.10.1) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
  • The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved in NT 3 Growth Factor Receptor (TrkC Tyrosine Kinase or GP145 TrkC or Neurotrophic Tyrosine Kinase Receptor Type 3 or NTRK3 or EC 2.7.10.1) targeted therapeutics and enlists all their major and minor projects
  • The report assesses NT 3 Growth Factor Receptor (TrkC Tyrosine Kinase or GP145 TrkC or Neurotrophic Tyrosine Kinase Receptor Type 3 or NTRK3 or EC 2.7.10.1) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type
  • The report summarizes all the dormant and discontinued pipeline projects
  • The report reviews latest news and deals related to NT 3 Growth Factor Receptor (TrkC Tyrosine Kinase or GP145 TrkC or Neurotrophic Tyrosine Kinase Receptor Type 3 or NTRK3 or EC 2.7.10.1) targeted therapeutics
Reasons to Purchase:
  • Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Identify and understand the targeted therapy areas and indications for NT 3 Growth Factor Receptor (TrkC Tyrosine Kinase or GP145 TrkC or Neurotrophic Tyrosine Kinase Receptor Type 3 or NTRK3 or EC 2.7.10.1)
  • Identify the use of drugs for target identification and drug repurposing
  • Identify potential new clients or partners in the target demographic
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
  • Devise corrective measures for pipeline projects by understanding NT 3 Growth Factor Receptor (TrkC Tyrosine Kinase or GP145 TrkC or Neurotrophic Tyrosine Kinase Receptor Type 3 or NTRK3 or EC 2.7.10.1) development landscape
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
READ MORE
Note: Product cover images may vary from those shown
2 of 5

FEATURED COMPANIES

  • AstraZeneca Plc
  • Daiichi Sankyo Co Ltd
  • Handok Inc
  • Ignyta Inc
  • Loxo Oncology Inc
  • Plexxikon Inc
  • MORE
Introduction

Report Coverage

NT 3 Growth Factor Receptor (TrkC Tyrosine Kinase or GP145 TrkC or Neurotrophic Tyrosine Kinase Receptor Type 3 or NTRK3 or EC 2.7.10.1) - Overview

NT 3 Growth Factor Receptor (TrkC Tyrosine Kinase or GP145 TrkC or Neurotrophic Tyrosine Kinase Receptor Type 3 or NTRK3 or EC 2.7.10.1) - Therapeutics Development

Products under Development by Stage of Development

Products under Development by Therapy Area

Products under Development by Indication

Products under Development by Companies

NT 3 Growth Factor Receptor (TrkC Tyrosine Kinase or GP145 TrkC or Neurotrophic Tyrosine Kinase Receptor Type 3 or NTRK3 or EC 2.7.10.1) - Therapeutics Assessment

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

NT 3 Growth Factor Receptor (TrkC Tyrosine Kinase or GP145 TrkC or Neurotrophic Tyrosine Kinase Receptor Type 3 or NTRK3 or EC 2.7.10.1) - Companies Involved in Therapeutics Development

AstraZeneca Plc

Daiichi Sankyo Co Ltd

Handok Inc

Ignyta Inc

Loxo Oncology Inc

Plexxikon Inc

NT 3 Growth Factor Receptor (TrkC Tyrosine Kinase or GP145 TrkC or Neurotrophic Tyrosine Kinase Receptor Type 3 or NTRK3 or EC 2.7.10.1) - Drug Profiles

AZD-7451 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

DS-6051 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

entrectinib - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

larotrectinib - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

LM-22B10 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Monoclonal Antibody to Agonize TrkC for Central Nervous System Disorders and Peripheral Nervous System Disorders - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

NOV-1601 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

PLX-7486 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

NT 3 Growth Factor Receptor (TrkC Tyrosine Kinase or GP145 TrkC or Neurotrophic Tyrosine Kinase Receptor Type 3 or NTRK3 or EC 2.7.10.1) - Dormant Products

NT 3 Growth Factor Receptor (TrkC Tyrosine Kinase or GP145 TrkC or Neurotrophic Tyrosine Kinase Receptor Type 3 or NTRK3 or EC 2.7.10.1) - Discontinued Products

NT 3 Growth Factor Receptor (TrkC Tyrosine Kinase or GP145 TrkC or Neurotrophic Tyrosine Kinase Receptor Type 3 or NTRK3 or EC 2.7.10.1) - Product Development Milestones

Featured News & Press Releases

Dec 20, 2017: Bayer announces initiation of rolling submission of new drug application in the U.S. for larotrectinib for the treatment of TRK fusion cancers

Dec 20, 2017: Loxo Oncology Initiates Rolling Submission of New Drug Application to U.S. Food and Drug Administration for Larotrectinib for the Treatment of TRK Fusion Cancers

Dec 07, 2017: Bayer to Highlight New Oncology Research on larotrectinib at ASH 2017

Dec 04, 2017: Updated larotrectinib pediatric clinical trial data demonstrate continued durability of response in TRK fusion cancers

Oct 18, 2017: Loxo Oncology Announces Positive Top-Line Results from Independent Review Committee Assessment of Larotrectinib Dataset

Oct 17, 2017: Ignyta Receives European Medicines Agency Prime Designation for Entrectinib in NTRK Fusion-Positive Solid Tumors

Oct 17, 2017: Interim Analysis of Ignytas Entrectinib Suggests Potential Best-in-Class Profile as a First-Line Targeted Therapy in Patients With ROS1-Positive Non-Small Cell Lung Cancer

Oct 17, 2017: Promising Phase 1/2 Results for Entrectinib Against ROS1+ Non-Small Cell Lung Cancer

Sep 27, 2017: Ignyta Announces Updated Data on Entrectinib in ROS1 NSCLC to Be Presented at the IASLC 18th World Conference on Lung Cancer

Sep 11, 2017: Ignyta to Provide Update on Entrectinib at ESMO 2017 Congress

Sep 07, 2017: Ignyta To Host Conference Call And Live Webcast On September 11 To Provide Pipeline Review, Including Lead Candidate Entrectinib

Sep 06, 2017: Ignyta Provides Regulatory Update on Entrectinib ROS1 Lung Cancer Development Program

Aug 31, 2017: Daiichi Sankyo to Present Data on Tumor Drug Candidate DS-6051 at the European Society for Medical Oncology 2017 Congress

Aug 30, 2017: Ignyta to Host Conference Call and Webcast on Entrectinib ROS1 Lung Cancer Update on September 6, 2017

Jul 10, 2017: Ignyta Receives FDA Orphan Drug Designation for Entrectinib for Treatment of NTRK Fusion-Positive Solid Tumors

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer

List of Tables:

Number of Products under Development by Stage of Development, H1 2018

Number of Products under Development by Therapy Areas, H1 2018

Number of Products under Development by Indications, H1 2018

Number of Products under Development by Indications, H1 2018 (Contd..1), H1 2018

Number of Products under Development by Companies, H1 2018

Products under Development by Companies, H1 2018

Products under Development by Companies, H1 2018 (Contd..1), H1 2018

Products under Development by Companies, H1 2018 (Contd..2), H1 2018

Number of Products by Stage and Mechanism of Actions, H1 2018

Number of Products by Stage and Route of Administration, H1 2018

Number of Products by Stage and Molecule Type, H1 2018

Pipeline by AstraZeneca Plc, H1 2018

Pipeline by Daiichi Sankyo Co Ltd, H1 2018

Pipeline by Handok Inc, H1 2018

Pipeline by Ignyta Inc, H1 2018

Pipeline by Loxo Oncology Inc, H1 2018

Pipeline by Plexxikon Inc, H1 2018

Dormant Projects, H1 2018

Discontinued Products, H1 2018

List of Figures:

Number of Products under Development by Stage of Development, H1 2018

Number of Products under Development by Therapy Areas, H1 2018

Number of Products under Development by Top 10 Indications, H1 2018

Number of Products by Mechanism of Actions, H1 2018

Number of Products by Stage and Mechanism of Actions, H1 2018

Number of Products by Stage and Route of Administration, H1 2018

Number of Products by Molecule Types, H1 2018

Number of Products by Stage and Molecule Types, H1
Note: Product cover images may vary from those shown
3 of 5

Loading
LOADING...

4 of 5
  • AstraZeneca Plc
  • Daiichi Sankyo Co Ltd
  • Handok Inc
  • Ignyta Inc
  • Loxo Oncology Inc
  • Plexxikon Inc
Note: Product cover images may vary from those shown
5 of 5
Note: Product cover images may vary from those shown
Adroll
adroll